J.P. Morgan analyst Robbie Marcus downgrades $DexCom (DXCM.US)$ to a hold rating, and adjusts the target price from $145 to $85.
According to TipRanks data, the analyst has a success rate of 55.7% and a total average return of 10.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $DexCom (DXCM.US)$'s main analysts recently are as follows:
DexCom's recent quarterly report has reinforced investor confidence in its 2025 revenue target, which incorporates a conservative projection from Stelo. It is anticipated that the company's earnings estimates may see an upward revision with the return to double-digit revenue growth.
DexCom's Q3 revenue exceeded expectations due to a record number of new patient starts, while earnings were influenced by reduced gross margins. The company is gaining momentum as the year ends, and there is a clear perspective for achieving at least 15% year-over-year growth in 2025.
DexCom's third-quarter sales surpassed expectations, bolstered by stronger-than-anticipated international performance, despite U.S. sales not meeting the general market predictions. This discrepancy is partially ascribed to the reduced number of new patients observed in the second quarter, coupled with anticipated effects from product mix variations. The company's forecast for sales and margins in 2024, along with its objectives for 2025, remain unchanged.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根大通分析師Robbie Marcus下調$德康醫療 (DXCM.US)$至持有評級，並將目標價從145美元下調至85美元。
根據TipRanks數據顯示，該分析師近一年總勝率為55.7%，總平均回報率為10.7%。
此外，綜合報道，$德康醫療 (DXCM.US)$近期主要分析師觀點如下：
德康醫療最近的季度報告進一步鞏固了投資者對其2025年營業收入目標的信心，這一目標包含了來自Stelo的保守預測。預計隨着公司回歸兩位數的營業收入增長，其盈利預估可能會有上調。
德康醫療的第三季度營收超出預期，主要受到新患者數量創紀錄增長的影響，而收益受到毛利率下降的影響。隨着年末的臨近，公司正蓄勢前行，2025年至少實現15%的年度增長目標有清晰的展望。
德康醫療的第三季度銷售超出預期，得益於強於預期的國際業績，儘管美國銷售未達到一般市場預測的水平。這種差異部分歸因於第二季度觀察到的新患者數量減少，以及產品組合變化所帶來的預期影響。公司對2024年銷售和利潤率的預測，以及對2025年目標的計劃仍然保持不變。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
